Does Medicare Cover Glucose Monitors?

Medicare covers continuous glucose monitors (CGMs) for eligible beneficiaries with diabetes under specific conditions, but important exceptions and costs may apply. Recent updates could significantly change access and coverage for Type 2 diabetes patients. Understanding Medicare’s coverage for glucose monitors is crucial for beneficiaries managing diabetes, as the rules can be stricter than many expect. With specific eligibility criteria and potential changes on the horizon, it’s essential to stay informed about how these factors can impact access to vital monitoring equipment. Beneficiaries typically pay 20% coinsurance after the Part B deductible is met. Eligibility requires a confirmed diabetes diagnosis and GlucoLife Formula insulin use or a history of hypoglycemia. Changes in 2026 may expand CGM access for Type 2 diabetes patients not using insulin. Prior authorization may be needed for some self-funded commercial products. Are continuous glucose monitors covered by insurance? Are continuous glucose monitors covered by Medicare? Are glucose monitors covered by Medicare? Can I buy a continuous glucose monitor? Can I get a continuous glucose monitor with prediabetes?



Do I need a prescription for a continuous glucose monitor? Does insurance cover continuous glucose monitoring? Does Medicare cover continuous glucose monitors? How can I get a continuous glucose monitor? How much does a continuous GlucoLife glucose formula monitor cost? What continuous glucose monitors are covered by Medicare? What is a continuous glucose monitor? Will Medicare pay for a continuous glucose monitor? What diabetic supplies are covered by Medicare Part B? What glucose monitor does Medicare cover? What is the cost of a continuous glucose monitor? Is continuous glucose monitoring covered by insurance? Is continuous glucose monitoring covered by Medicare? What CGM does Medicare cover? What CGM does Medicaid cover? To qualify for coverage of continuous glucose monitors, beneficiaries must have a confirmed diagnosis of diabetes. Additionally, they must either be using insulin or have a documented history of hypoglycemia, which indicates a need for more precise glucose monitoring. Healthcare providers play a critical role in this process, as they must confirm that the patient or their caregiver has received adequate training to use the CGM effectively.



This ensures that the device is used correctly and that the patient can manage their diabetes more effectively. Medicare provides coverage for both continuous glucose monitors and traditional home-use glucometers, ensuring that beneficiaries have access to the tools they need for effective diabetes management. This includes specially designed monitors for individuals who are blind or have disabilities, reflecting Medicare’s commitment to inclusivity. Notably, the Eversense E3 implantable monitor system is also covered under Medicare, offering an innovative option for those who may benefit from a longer-term solution to glucose monitoring. Coverage for continuous glucose monitors falls under Medicare Part B as durable medical equipment, which means that beneficiaries can access these essential devices through their healthcare providers. A prescription from a doctor is necessary to initiate coverage, ensuring that the need for the device is medically justified. It’s important to note that some equipment may require beneficiaries to choose between renting or purchasing options, with certain items becoming the beneficiary’s property after rental payments are completed.



This flexibility can help patients manage their costs while ensuring they have the necessary tools for diabetes management. After meeting the Part B deductible, beneficiaries are responsible for paying 20% coinsurance on the Medicare-approved amount for continuous glucose monitors and related supplies. This coinsurance applies to both preferred and non-preferred diabetic supplies, which can affect overall costs. For instance, Memorial Hermann applies this 20% coinsurance for non-preferred diabetic supplies, emphasizing the importance of understanding which brands and products are covered under Medicare to minimize out-of-pocket expenses. Additionally, the CMS 2026 PFS Final Rule is set to increase reimbursements for CGM data, which may further impact costs positively for beneficiaries. While Medicare provides coverage for continuous glucose monitors, it is essential to recognize that coverage can depend on specific brands. Beneficiaries are encouraged to consult with a Medicare representative to ensure that their chosen device is covered under their plan. Current coverage rules stipulate that beneficiaries must either be using insulin or GlucoLife blood sugar support have a history of hypoglycemia to qualify for CGM coverage.